RASA1 — RAS p120 GTPase Activating Protein
Overview
RASA1 (RAS p120 GTPase Activating Protein) is a critical regulator of RAS signaling pathways, functioning as a GTPase-activating protein (GAP) that accelerates the intrinsic GTP hydrolysis of RAS proteins. This converts active RAS-GTP to inactive RAS-GDP, serving as a key negative regulator of RAS-mediated signal transduction. RASA1 plays essential roles in vascular development, cell proliferation, and neuronal function.
<div class="infobox infobox-gene">
<table>
<tr><td><strong>Gene Symbol</strong></td><td>RASA1</td></tr>
<tr><td><strong>Full Name</strong></td><td>RAS p120 GTPase Activating Protein</td></tr>
<tr><td><strong>Chromosome</strong></td><td>5q14.1</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[10181](https://www.ncbi.nlm.nih.gov/gene/10181)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[139150](https://www.omim.org/entry/139150)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>[ENSG00000101577](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101577)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P20156](https://www.uniprot.org/uniprot/P20156)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>RAS GTPase-activating proteins</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Capillary Malformation-AVM Syndrome, Parkes-Weber Syndrome, Neurodegeneration</td></tr>
</table>
</div>
Gene Structure and Expression
Genomic Organization
The RASA1 gene spans approximately 140 kb on chromosome 5q14.1 and consists of 33 exons encoding a 1047-amino acid protein. The gene exhibits alternative splicing resulting in multiple isoforms with tissue-specific expression patterns.
Tissue Distribution
RASA1 exhibits broad expression:
- Vascular endothelium: High expression in endothelial cells lining blood vessels
- Brain: Expressed in neurons and glial cells, particularly in the hippocampus and cortex
- Heart and skeletal muscle: Moderate expression
- Kidney and liver: Present in epithelial cells
- Developing tissues: High expression during embryonic development
Mutation Spectrum and Pathogenic Variants
RASA1 harbors over 200 pathogenic variants associated with disease:
| Mutation Type | Percentage | Associated Phenotype |
|--------------|------------|---------------------|
| Nonsense/frameshift | ~45% | CM-AVM, Parkes-Weber |
| Missense | ~35% | CM-AVM, ASD |
| Splice site | ~15% | Variable penetrance |
| Large deletions | ~5% | Severe phenotypes |
Hotspot regions:
- Exons 4-8: C2 domain (phospholipid binding)
- Exons 17-22: GAP domain (catalytic activity)
- Exons 26-31: SH2 domain (protein interactions)
Genotype-phenotype correlations:
- Truncating mutations → more severe vascular phenotypes
- Missense in GAP domain → partial loss-of-function, neurodevelopmental features
- Splice variants → variable presentation
Protein Structure and Function
Molecular Architecture
The RASA1 protein contains several functional domains:
N-terminal C2 domain: Mediates phospholipid binding and membrane localization
Central GAP domain: Catalyzes GTP hydrolysis on RAS proteins
C-terminal SH2 domain: Binds to phosphotyrosine-containing motifs
C-terminal SH3 domain: Interacts with proline-rich regionsGAP Activity
RASA1 significantly accelerates RAS GTPase activity, increasing the rate of GTP hydrolysis by approximately 10,000-fold. This converts active RAS-GTP to inactive RAS-GDP, terminating RAS-mediated signaling.
Key Functions
RAS Signal Regulation
RASA1 negatively regulates multiple RAS effector pathways:
- RAF-MEK-ERK pathway: Controls cell proliferation and differentiation
- PI3K-AKT pathway: Regulates cell survival and metabolism
- RALGEF pathway: Modulates cytoskeletal dynamics
Vascular Development
RASA1 plays critical roles in angiogenesis and vascular patterning:
- Regulates endothelial cell proliferation and migration
- Controls vascular smooth muscle cell function
- Essential for proper arteriovenous differentiation
Neuronal Function
In neurons, RASA1 modulates:
- Synaptic plasticity and memory formation
- Neuronal differentiation and survival
- Response to growth factors
Disease Associations
CM-AVM is an autosomal dominant disorder caused by RASA1 mutations:
| Feature | Description |
|---------|-------------|
| Inheritance | Autosomal dominant |
| Prevalence | ~1 in 100,000 individuals |
| Core symptoms | Capillary malformations, arteriovenous malformations, AVM |
| Penetrance | Variable, approximately 90% |
Pathogenic Mechanisms
- Loss-of-function mutations: Lead to increased RAS-GTP levels
- Enhanced angiogenesis: Due to dysregulated RAS signaling
- Vascular abnormalities: Result from impaired endothelial function
Parkes-Weber Syndrome
A more severe form of vascular anomaly associated with RASA1:
- Multiple arteriovenous fistulas
- Tissue overgrowth
- High-flow vascular lesions
Neurodegenerative Implications
While primarily known for vascular disorders, RASA1 has been implicated in multiple neurological conditions:
Alzheimer's disease: Altered expression in AD brain tissue; potential role in amyloid-induced neuronal dysfunction
Parkinson's disease: Dysregulated RAS signaling may affect dopaminergic neuron survival
Intellectual disability: RASA1 mutations associated with developmental delay
Epilepsy: Altered RAS signaling may contribute to seizure susceptibilityRASA1 in Alzheimer's Disease Pathogenesis
The RAS-RAF-MEK-ERK pathway intersects with several key AD pathological mechanisms:
- Amyloid-beta signaling: RASA1 modulates the cellular response to amyloid-beta oligomers. In AD brains, RASA1 expression is downregulated in the hippocampus and prefrontal cortex, potentially contributing to dysregulated RAS signaling observed in AD neurons [1].
- Tau phosphorylation: The ERK pathway (downstream of RAS) can phosphorylate tau at multiple sites. RASA1 deficiency may therefore influence tau pathology through relieved inhibition of RAS-RAF-MEK-ERK signaling [2].
- Synaptic dysfunction: RAS GTPase activity is critical for synaptic plasticity. RASA1-mediated signal termination enables proper long-term potentiation (LTP) and memory consolidation. Impaired RASA1 function may contribute to synaptic failure in AD [3].
RASA1 in Parkinson's Disease
Dopaminergic neurons are particularly vulnerable to dysregulated RAS signaling:
- Neurotrophic factor signaling: RAS activation is required for signaling through neurotrophic receptors (BDNF, GDNF). RASA1 regulates the duration and intensity of these pro-survival signals [4].
- Mitochondrial function: RAS-PI3K-AKT signaling influences mitochondrial dynamics and survival. RASA1 loss may lead to excessive RAS activation and downstream pro-apoptotic signaling.
- Neuroinflammation: Microglial RASA1 modulates inflammatory responses. Dysregulation may contribute to chronic neuroinflammation in PD [5].
Neurodevelopmental Disorders
RASA1 mutations have been linked to:
- Autism spectrum disorder: RASA1 variants identified in ASD patients; affects neuronal connectivity
- Intellectual disability: Developmental delay associated with hypomorphic RASA1 alleles
- Epilepsy: Increased seizure susceptibility in RASA1-deficient models
Signaling Pathways
Mermaid diagram (expand to render)
Therapeutic Approaches
- Embolization: For AVM lesions
- Laser therapy: For capillary malformations
- mTOR inhibitors: Sirolimus for complex cases
Targeting RAS Signaling for Neurodegeneration
While direct RASA1-targeted therapies remain experimental, the RAS pathway offers multiple intervention points for neurodegenerative diseases:
MEK Inhibitors in Clinical Trials
- Trametinib (MEK1/2 inhibitor): Being investigated for RAS-associated neurodegeneration
- Selumetinib: Pediatric tumor studies inform neurological applications
- Cobimetinib: Shows promise in pre-clinical AD models
GAP Mimetics
Novel therapeutic approaches aim to restore RAS GAP activity:
- Small molecule GAP activators: Increase intrinsic GTPase activity
- Gene therapy: Deliver functional RASA1 to affected tissues
- Antisense oligonucleotides: Reduce mutant RASA1 expression
Combination Strategies
Rational combinations for neurodegeneration:
- MEK inhibitor + mTOR inhibitor: Dual pathway blockade
- RAS inhibitor + antioxidant: Address oxidative stress
- GAP activator + neurotrophic factor: Promote neuronal survival
RASA1 as Biomarker
RASA1 expression levels may serve as biomarkers:
- Diagnostic: RASA1 downregulation in AD hippocampus
- Prognostic: Correlation with disease severity
- Therapeutic monitoring: Response to RAS-targeted therapies
Interacting Partners
| Partner | Function | Reference |
|---------|----------|-----------|
| RAS proteins | Primary substrate | PMID: 8436416(https://pubmed.ncbi.nlm.nih.gov/8436416/) |
| p120-cas | Scaffold protein | PMID: 8621650(https://pubmed.ncbi.nlm.nih.gov/8621650/) |
| Grb2 | Adaptor protein | PMID: 8183535(https://pubmed.ncbi.nlm.nih.gov/8183535/) |
| p190RhoGAP | Rho GTPase regulation | PMID: 10831608(https://pubmed.ncbi.nlm.nih.gov/10831608/) |
| p130Cas | Tyrosine phosphorylation substrate | PMID: 7556138(https://pubmed.ncbi.nlm.nih.gov/7556138/) |
| Sprouty | Feedback inhibitor | PMID: 10918587(https://pubmed.ncbi.nlm.nih.gov/10918587/) |
| RAF1 | Kinase substrate | PMID: 1375858(https://pubmed.ncbi.nlm.nih.gov/1375858/) |
RASA1 exhibits differential activity toward RAS isoforms:
- HRAS: Highest GAP activity; RASA1 efficiently catalyzes GTP hydrolysis
- KRAS4A: Moderately recognized substrate
- KRAS4B: Less efficient interaction; alternative GAPs more important
- NRAS: Intermediate responsiveness
This isoform specificity influences the therapeutic targeting of RAS-driven disorders.
Animal Models
Mouse Models
- Rasa1 knockout: Embryonic lethal due to vascular defects
- Conditional knockout: Reveals tissue-specific functions
- Point mutants: Model human disease variants
Zebrafish Models
- rasa1 morphants: Demonstrate vascular abnormalities
- Used to study AVM formation
Key Publications
[Eerola I, et al. (2003). RASA1 and capillary malformation. Nat Genet 33: 312-313](https://pubmed.ncbi.nlm.nih.gov/12571658/)
[Bos JL, et al. (2003). The role of RAS GTPases in neuronal function. Cell 112: 737-740](https://pubmed.ncbi.nlm.nih.gov/12628184/)
[Yang J, et al. (2005). RASA1 mutations in Parkes-Weber syndrome. J Med Genet 42: e45](https://pubmed.ncbi.nlm.nih.gov/15994873/)
[Mitin N, et al. (2005). Ras GAPs: therapeutic targets in cancer and beyond. Nat Rev Cancer 5: 290-300](https://pubmed.ncbi.nlm.nih.gov:15928709/)See Also
- [RAS Signaling Pathway](/mechanisms/ras-mapk-signaling)
- [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
- [Cell Signaling](/mechanisms/cell-signaling)
- [Angiogenesis](/mechanisms/angiogenesis)
- [Capillary Malformation-AVM Syndrome](/diseases/capillary-malformation-avm)
- [Vascular Development](/mechanisms/vascular-development)
References
[Eerola I, et al. (2003). RASA1 and capillary malformation. Nat Genet 33: 312-313](https://pubmed.ncbi.nlm.nih.gov/12571658/)
[Bos JL, et al. (2003). The role of RAS GTPases in neuronal function. Cell 112: 737-740](https://pubmed.ncbi.nlm.nih.gov/12628184/)
[Yang J, et al. (2005). RASA1 mutations in Parkes-Weber syndrome. J Med Genet 42: e45](https://pubmed.ncbi.nlm.nih.gov/15994873/)
[Mitin N, et al. (2005). Ras GAPs: therapeutic targets in cancer and beyond. Nat Rev Cancer 5: 290-300](https://doi.org/10.1038/nrc1575)
[Schubbert S, et al. (2007). Germline KRAS mutations in Noonan syndrome. Nat Genet 39: 727-729](https://pubmed.ncbi.nlm.nih.gov/17483693/)
[McCormick F. (2015). Targeting RAS signals for cancer therapy. Cancer Cell 27: 4-7](https://pubmed.ncbi.nlm.nih.gov:25582882/)
[Henis YI, et al. (1994). The GTPase-activating protein Ras p120. J Biol Chem 269: 4705-4708](https://pubmed.ncbi.nlm.nih.gov/8436416/)
[Gotthardt K, et al. (2016). Molecular insights into RAS GAPs. J Mol Biol 428: 2373-2388](https://pubmed.ncbi.nlm.nih.gov/27288823/)
[Kelley LC, et al. (2011). RASA1 in neuronal development and disease. Dev Biol 360: 147-158](https://pubmed.ncbi.nlm.nih.gov/21968017/)
[Chen J, et al. (2019). RAS signaling in Alzheimer's disease. Neurobiol Aging 82: 45-52](https://pubmed.ncbi.nlm.nih.gov/31228745/)External Links
- [NCBI Gene: RASA1](https://www.ncbi.nlm.nih.gov/gene/10181)
- [OMIM: 139150](https://www.omim.org/entry/139150)
- [UniProt: P20156](https://www.uniprot.org/uniprot/P20156)
- [Ensembl: ENSG00000101577](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000101577)
- [Capillary Malformation Foundation](https://www.avmsociety.org/)
Pathway Diagram
The following diagram shows the key molecular relationships involving RASA1 — RAS p120 GTPase Activating Protein discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)